Bellerophon Therapeutics announced positive topline data from the phase 2b study of INOpulse® (pulsed, inhaled nitric oxide) delivery system for the treatment of pulmonary hypertension associated with pulmonary fibrosis (PH-PF).
Incorporating preoperative right heart measurements into the standard pulmonary hypertension risk estimation model may allow for better risk stratification following aortic valve replacement.
Systemic anticoagulation was found to improve quality-adjusted life years among patients with idiopathic pulmonary arterial hypertension but not among those with connective tissue disease-associated pulmonary arterial hypertension.
Bellerophon Therapeutics announced positive topline results from cohort 2 of an ongoing phase 2/3 iNO-PF study of INOpulse delivery system for the treatment of PH-ILD.
In patients with abnormal vital signs presenting to the emergency department who are suspected of having a pulmonary embolism, a negative focused cardiac ultrasound examination may be associated with reduced odds of a pulmonary embolism diagnosis.
A new consensus survey of expert opinions was published regarding the use of oral prostacyclin pathway agents in patients with various forms of pulmonary arterial hypertension.
Treatment with noninvasive ventilation and continuous positive airway pressure provided similar improvements in pulmonary hypertension and left ventricular diastolic dysfunction in obesity hypoventilation syndrome and concomitant severe obstructive sleep apnea.
Similar to results among people who smoked traditional cigarettes, e-cigarette smoking negatively effects heart disease risk factors, namely, cholesterol, triglycerides and glucose levels, and decreases blood flow in the heart.
In patients with pulmonary arterial hypertension, cardiac magnetic resonance imaging metrics are capable of identifying individuals at a low risk for 1-year mortality.
